Dostarlimab-gxly, GlaxoSmithKline, Jemperli
Dostarlimab-gxly with chemotherapy is approved by the FDA for endometrial cancer
August 2023: Dostarlimab-gxly (Jemperli, GlaxoSmithKline), followed by dostarlimab-gxly as a single agent, was approved by the Food and Drug Administration for the treatment of primary advanced or recurrent endometrial cancer (EC..
dMMR, Dostarlimab-gxly, GlaxoSmithKline, Jemperli
Dostarlimab-gxly is approved by FDA for dMMR endometrial cancer
Feb 2023: Dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) was given FDA approval to treat adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progressed during or after a prior ..
dostarlimab, Gina Kolata, GlaxoSmithKline, Luis A. Diaz Jr, NEJM
All participants in a small cancer trial achieved complete remission
June 2022: A small study of rectal cancer patients yielded extraordinary results: 100 percent of the individuals were in remission. The results were published in The New England Journal of Medicine this week.The trial was funded ..